See more : Hwang Kum Steel & Technology Co., Ltd (032560.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Kindstar Globalgene Technology, Inc. (9960.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kindstar Globalgene Technology, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- NCR Corporation (NCR) Income Statement Analysis – Financial Results
- Skeena Resources Limited (SKE) Income Statement Analysis – Financial Results
- Repsol, S.A. (REPYY) Income Statement Analysis – Financial Results
- Allin Corporation (ALLN) Income Statement Analysis – Financial Results
- King House CO., Ltd. (4419.TWO) Income Statement Analysis – Financial Results
Kindstar Globalgene Technology, Inc. (9960.HK)
About Kindstar Globalgene Technology, Inc.
Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 967.26M | 1.39B | 930.67M | 891.39M | 832.79M | 706.20M |
| Cost of Revenue | 516.13M | 783.54M | 444.90M | 430.41M | 380.58M | 327.81M |
| Gross Profit | 451.13M | 603.06M | 485.77M | 460.98M | 452.21M | 378.40M |
| Gross Profit Ratio | 46.64% | 43.49% | 52.20% | 51.71% | 54.30% | 53.58% |
| Research & Development | 105.34M | 101.23M | 90.33M | 75.28M | 79.02M | 73.58M |
| General & Administrative | 105.63M | 80.41M | 99.58M | 29.19M | 13.78M | 12.14M |
| Selling & Marketing | 307.78M | 360.56M | 282.24M | 248.52M | 274.60M | 249.53M |
| SG&A | 413.41M | 440.97M | 381.82M | 277.71M | 288.38M | 261.67M |
| Other Expenses | -67.62M | -9.69M | -23.95M | 14.96M | 27.02M | -70.66M |
| Operating Expenses | 451.13M | 532.50M | 448.19M | 367.96M | 394.42M | 358.93M |
| Cost & Expenses | 967.26M | 1.32B | 893.09M | 798.37M | 774.99M | 686.74M |
| Interest Income | 82.83M | 51.31M | 12.50M | 3.48M | 4.78M | 3.72M |
| Interest Expense | 8.03M | 2.52M | 1.81M | 2.33M | 3.54M | 4.19M |
| Depreciation & Amortization | 75.03M | 64.89M | 57.43M | 50.80M | 42.60M | 37.77M |
| EBITDA | 126.38M | 150.72M | -1.39B | -909.23M | -122.47M | -17.45M |
| EBITDA Ratio | 13.07% | 14.19% | -149.64% | -100.99% | -14.08% | -1.59% |
| Operating Income | 0.00 | 131.89M | -1.45B | -951.04M | -159.89M | 19.47M |
| Operating Income Ratio | 0.00% | 9.51% | -155.81% | -106.69% | -19.20% | 2.76% |
| Total Other Income/Expenses | 43.32M | -48.57M | -3.91M | -11.32M | -8.71M | -78.88M |
| Income Before Tax | 43.32M | 83.32M | -1.45B | -962.35M | -168.61M | -59.42M |
| Income Before Tax Ratio | 4.48% | 6.01% | -156.23% | -107.96% | -20.25% | -8.41% |
| Income Tax Expense | 6.88M | 5.83M | 246.00K | 7.77M | 977.00K | -5.07M |
| Net Income | 41.29M | 75.46M | -1.45B | -970.12M | -169.58M | -52.67M |
| Net Income Ratio | 4.27% | 5.44% | -156.26% | -108.83% | -20.36% | -7.46% |
| EPS | 0.04 | 0.09 | -2.93 | -1.08 | -0.19 | -0.06 |
| EPS Diluted | 0.04 | 0.09 | -2.93 | -1.07 | -0.19 | -0.06 |
| Weighted Avg Shares Out | 971.44M | 795.38M | 495.61M | 901.03M | 901.03M | 905.62M |
| Weighted Avg Shares Out (Dil) | 970.76M | 817.96M | 495.61M | 905.62M | 905.62M | 905.62M |
Source: https://incomestatements.info
Category: Stock Reports